Evidence map›Paper›PMID 39117938›Full record

ArticleTherapeutic innovation & regulatory science2024

RegionSizeR- A Novel App for Regional Sample Size Planning in MRCTs.

Guannan Sun, Xin Sun, Huijuan Su, Yuqin Liao, Di Wei, Hanqing Ma, Xinyu Li, Ran Fan, Xiaowei Ren

Abstract read
In one paragraph

Article in Therapeutic innovation & regulatory science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guannan SunPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Xin SunPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Huijuan SuPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Yuqin LiaoPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Di WeiPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Hanqing MaPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China.
Xinyu LiBayer US LLC, Whippany, NJ, USA.
Ran FanAkesobio Inc, Nanjing, China.
Xiaowei RenPharmaceuticals Statistics and Data Insights, Bayer Healthcare Co. Ltd. Research & Development, 6F Parkview Green Blk B, No.9 Dongdaqiao Road, Beijing, China. Xiaowei.ren@bayer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In multi-regional clinical trials, planning the sample size for participating regions is essential for the evaluation of the treatment effect consistency across regions. Based on the MRCT design and sample size allocation to regions, consistency probability is usually used to predict the consistent trend between regions and the overall population, while preserving a certain proportion of the overall treatment effect. Specific enrollment characteristics in a region of interest should also be considered during the time of the sample size planning. To facilitate efficient and harmonized regional sample size planning, we have developed RegionSizeR, a comprehensive and user-friendly interactive web-based R shiny application that can be obtained from https://github.com/rsr-ss/RegionSizeR . This simulation-based app can serve as an initial point for discussions on sample size allocation plans, following preservation of treatment effect method in ICH E17. The app accommodates various types of endpoints and designs, including continuous, binary, and time-to-event endpoints, for superiority, non-inferiority, and MCP-Mod designs. To ensure the validity of this app, independent testing is conducted allowing a discrepancy of no more than 1% across all results considering various scenarios.

Indexed as

Research DesignClinical Trials as TopicComputer SimulationHumansMulticenter Studies as TopicSample SizeSoftwareClinical trialConsistency probabilityPreservation of treatment effectRegions joining MRCTSample size

Identifiers

PMID39117938
PMCPMC11530476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.